ERBB2 and breast cancer: However, a substantial proportion of breast cancer patients do not respond to this drug, Targeting Her-2 alone by trastuzumab may, under some conditions, not be sufficient to halt the rapid growth of tumor cells that also express high levels of Lin28A.